title: Early U.S. Experience Following FDA Approval of the ABBOTT Vascular Bioresorbable Vascular Scaffold: Optimal Deployment Technique Using High Resolution Coronary Artery Imaging.
abstract: Drug eluting metallic stents have been the "gold standard" in the percutaneous management of coronary artery disease. Recent publications have suggested that the ABSORBTM bioresorbable vascular scaffold (BVS) may represent a reasonable alternative, in well selected cases.
authors: Department of Cardiology, HonorHealth and the Scottsdale-Lincoln Health Network, Scottsdale, Arizona. davidrizik@aol.com.
authors: David G
authors: DG
authors: Rizik
authors: Department of Cardiology, HonorHealth and the Scottsdale-Lincoln Health Network, Scottsdale, Arizona.
authors: Bimal B
authors: BB
authors: Padaliya
mesh_terms: D020341:Absorbable Implants; D003324:Coronary Artery Disease / Q000000981:diagnostic imaging / Q000628:therapy; D003331:Coronary Vessels / Q000000981:diagnostic imaging*; D018795:Device Approval; D054855:Drug-Eluting Stents; D006801:Humans; D018579:Patient Selection; D062645:Percutaneous Coronary Intervention / Q000295:instrumentation* / Q000379:methods; D011358:Product Surveillance, Postmarketing; D054457:Tissue Scaffolds; D016896:Treatment Outcome; D014481:United States